Skip to main content

Table 1 Participant characteristics

From: Lower circulating endocannabinoid levels in children with autism spectrum disorder

 

Neurotypical control

Children with ASD

N

93

93

Age

11.8 ± 4.3

13.1 ± 4.1^

% male

79%

79%

BMI

21.0 ± 4.2

20.4 ± 5.5

Epilepsy comorbidity

0%

10%

High ASD symptoms severity

 ADOS comparison score = 8–10

 

77%

 VABS standard score ≤ 70

 

88%

 CARS total score ≥ 37

 

81%

 SRS t scores ≥ 75

 

86%

Psychotropic medications*

 Any

 

80%

 Antipsychotic

 

56%

 SSRIs

 

23%

 Stimulants

 

15%

 Antiepileptic (mood stabilizers)

 

13%

 Benzodiazepines

 

8%

 Others

 

5%

  1. ^Significant age difference (P = 0.040). The BMI difference was not significant
  2. *Medications were stable for at least 1 month before blood collection. Antipsychotic (n): risperidone (21), aripiprazole (16), clotiapine (10), periciazine (10), olanzapine (5), promethazine (3), quetiapine fumarate (seroquel, 3), methotrimeprazine (1). SSRIs selective serotonin reuptake inhibitors (n): fluoxetine (15), fluvoxamine (2), sertraline (2), escitalopram (1), trazodone (1). Stimulants (n): methylphenidate (11), lisdexamfetamine (2). Antiepileptic (n): valproic acid (7), carbamazepine (1), lamotrigine (1), topiramate (1), stiripentol (1), sulthiame (1). Benzodiazepines (n): clobazam (3), clonazepam (3), zolpidem (1). Others (n): guanfacine (2), propranolol (2), enalapril (1)